The MDM2-p53 interaction has also been implicated in the regulation of glucolipid metabolism in the liver, where its dysregulation contributes to metabolic diseases such as metabolic syndrome and non-alcoholic fatty liver disease (NAFLD), conditions that can progress to HCC under certain circumstances (Guillen-Sacoto et al., 2017[74]). This evidence concerns the gene TP53 and metabolic dysfunction-associated steatotic liver disease.